NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ardent Health, Inc. (NYSE: ARDT). Shareholders who purchased shares of ARDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ardent-health-inc-loss-submission-form/?id=183178&from=3 CLASS PERIOD: July 18, ...

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2][9] Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][3] Market Reaction - Following the release of a report by activist short-seller Blue Orca Capital, Nutex's stock dropped over 10%, reflecting investor concerns about the company's reliance on arbitration reimbursements [3][4] Financial Misrepresentation - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - Nutex's shares fell 16.39% after the company announced a delay in its Form 10-Q filing due to "non-cash accounting adjustments" [6] Audit Findings - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7] Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [9] Ongoing Investigations - Law firm Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting practices [10]

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][4]. - The complaint asserts that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [3]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital accusing HaloMD of fraud, Nutex's stock dropped over 10%, indicating investor concern [4][5]. - After Nutex delayed its Form 10-Q submission, shares plummeted 16.39% the next day, closing at $92.91 [7]. Group 3: Financial Reporting Issues - The lawsuit highlights misrepresentation in Nutex's financial controls, particularly regarding the classification of stock-based compensation obligations [6]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations related to hospital development [8]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [10][11]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [12].